Article
Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
Authors:
Kara Rossfeld,
Division of Surgical Oncology, The Ohio State University College of Medicine, Columbus, OH, US
About Kara
MD
Erinn M. Hade,
Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University College of Medicine, Columbus, OH, US
About Erinn M.
PhD
Alexandra Gangi,
H. Lee Moffitt Cancer Center, Tampa, FL, US
About Alexandra
MD
Matthew Perez,
H. Lee Moffitt Cancer Center, Tampa, FL, US
About Matthew
MD
Emily N. Kinsey,
Division of Medical Oncology, Duke University, Durham, NC, US
About Emily N.
MD
Joanna Grabska,
H. Lee Moffitt Cancer Center, Tampa, FL, US
About Joanna
MD
Ashley Ederle,
Division of Medical Oncology, Duke University, Durham, NC, US
About Ashley
BA
Jonathan Zager,
H. Lee Moffitt Cancer Center, Tampa, FL, US
About Jonathan
MD
April K. Salama,
Division of Medical Oncology, Duke University, Durham, NC, US
About April K.
MD
Thomas E. Olencki,
Department of Internal Medicine, Division of Medical Oncology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, US
About Thomas E.
DO
Georgia M. Beasley
Duke University Medical center 3118, Durham, NC 27710, 489 Seeley Mudd Building, US
About Georgia M.
MD
Abstract
Background: Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and toxicities can be severe leaving need for reliable clinical predictive markers.
Methods: We examined primary tumor characteristics including ulceration, BRAF mutation status, and Breslow depth in patients who subsequently developed stage IV disease and were treated with ipilimumab at 3 institutions. Patients in this study were not treated on clinical trials. To investigate the relationship between patient characteristics at the time of diagnosis and survival following melanoma diagnosis we utilized Cox proportional hazards models, accounting for delayed entry into the study cohort. Cox models estimate the age and institution adjusted hazard ratios for risk of death.
Results: Of patients (n= 385) treated with ipilimumab for stage IV melanoma, 302 met inclusion criteria. The complete response to ipilimumab was 5%, partial response was 13%, 18% had stable disease, 62% had progressive disease, and 5 unknown. The median overall survival rate was 2.03 years [95% confidence interval (CI): 0.13, 3.05]. Primary tumor Breslow depth, lymphovascular invasion, BRAF status, and ulceration did not predict sensitivity to ipilimumab. In this study patient cohort, BRAF mutation (adjusted hazard ratio: 1.43, 95% CI: 0.98, 2.07) and presence of ulceration (adjusted hazard ratio: 1.47, 95% CI: 0.95, 2.26) contributed to an increased risk of death.
Conclusions: The presence of ulceration did not correlate with sensitivity to ipilimumab. Ulceration of the primary tumor and a BRAF mutation were moderately associated with worse survival in patients with metastatic melanoma treated with ipilimumab.
How to Cite:
Rossfeld K, Hade EM, Gangi A, Perez M, Kinsey EN, Grabska J, et al.. Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics. International Journal of Surgery: Oncology. 2017;2(9):e43. DOI: http://doi.org/10.1097/IJ9.0000000000000043
Published on
10 Oct 2017.
Peer Reviewed
Downloads
